Two large scale trials were conducted in parallel, Studies of PCSK9 Inhibition and the Reduction of Vascular Events (SPIRE) −1 and −2’, and the trials randomized 27,438 cardiovascular disease or high risk patients. The gene discussed is PCSK9; the disease is cardiovascular disorder.